|
Patent landscape, scope, and claims: |
United States Patent 11,738,085 (Meloxicam + Rizatriptan Bicarbonate Tablet): Scope, Claim Architecture, and US Patent Landscape
US Patent 11,738,085 claims a tightly specified oral fixed-dose combination (FDC) and administration regimen for migraine: a single daily tablet containing meloxicam (about 20 mg), rizatriptan (about 10 mg or salt molar equivalent; dependent claims narrow to ~14–15 mg rizatriptan salt), and a bicarbonate excipient load (about 400 mg to about 1000 mg) designed to shift meloxicam exposure (Tmax, Cmax, AUC) and produce pain reduction observed at about 2 hours or less. The claim set is largely exposure-method and formulation-limitation driven, which increases validity leverage against “different formulation” design-arounds but also narrows infringement to products that hit the stated pharmacokinetic (PK) and dose ranges.
What exactly does US 11,738,085 claim: method-of-treating migraine with specific FDC dose and PK targets?
Core independent claim (Claim 1)
- Indication and regimen: “method of treating migraine” by orally administering one tablet daily to a human.
- Tablet composition (quantitative)
- Meloxicam: about 20 mg or molar equivalent salt form.
- Rizatriptan: about 10 mg or molar equivalent salt form.
- Bicarbonate: about 400 mg to about 1000 mg.
- Outcome/observation timing: administration results in reduction of pain observed at about two hours or less after administration.
- Practical read: claim is a combination of (1) dosing, (2) formulation excipient window, and (3) a patient-response time constraint.
Dependent claim structure (Claims 2–9 and 10–29)
- PK-dependent sublimitations (meloxicam exposure)
- Tmax constraints
- Claim 2: Tmax < 60 minutes.
- Claim 3: Tmax = about 5×10^1 minutes (interpretable as ~50 minutes if literally 5×10^1).
- Cmax constraints
- Claim 4: Cmax 2,500–3,000 ng/mL.
- Claim 5: Cmax about 3×10^3 ng/mL (≈3,000 ng/mL).
- AUC constraints
- Claim 6: AUC0-inf 50,000–70,000 ng·hr/mL.
- Claim 7: AUC0-inf 50,000–60,000 ng·hr/mL.
- Claim 8: AUC0-inf about 5×10^4 ng·hr/mL (≈50,000 ng·hr/mL).
- Half-life
- Claim 9: mean elimination half-life about 20 hours for meloxicam.
- Rizatriptan salt quantity narrowing
- Claim 10–12: about 14 mg, 15 mg, or 14–15 mg salt form.
- Meloxicam quant narrowing
- Claim 13: about 20 mg meloxicam.
- Claim 18: depends on Claim 13; re-anchors meloxicam at about 20 mg.
- Bicarbonate salt type
- Claim 17: bicarbonate comprises sodium bicarbonate.
- Salt identity
- Claim 29: rizatriptan is rizatriptan benzoate.
- Repeating PK windows under the meloxicam-quantified dependent set
- Claims 22–28 mirror Claims 2–8 but in the “Claim 18” branch (meloxicam fixed at ~20 mg).
Key consequence: infringement is fact-intensive and likely pivots on whether a commercial product’s tablet composition and in-human PK/response match the claimed targets (Tmax/Cmax/AUC and pain reduction at ≤2 hours).
How broad is the claim scope in US 11,738,085: “about” ranges vs tightly defined PK windows?
Breadth levers (more permissive)
- Use of “about” on dose amounts (meloxicam ~20 mg; rizatriptan ~10 mg; bicarbonate 400–1000 mg).
- Salt form equivalents: claim covers “salt form” molar equivalents for meloxicam and rizatriptan (but dependent claims narrow salt identities and quantities).
- Pain reduction “observed at about two hours or less” adds a clinical timing element, but “about” softens the boundary.
Narrowing levers (more restrictive)
- Single tablet daily is a regimen limitation.
- Bicarbonate load window (400–1000 mg) is quantitative and likely constrains formulation excipient selection and total tablet weight.
- Dependent claims lock in meloxicam PK signatures:
- Tmax < 60 minutes and specific numeric values (Claim 3).
- Cmax and AUC windows with narrow ranges (Claims 4–8).
- Half-life ≈20 hours (Claim 9).
- Dependent claims lock rizatriptan salt mass ranges (14–15 mg salt) and specific salt identities (benzoate in Claim 29) and sodium bicarbonate in Claim 17.
Practical claim map
- Claim 1 is the broadest (composition + method + clinical timing).
- Claims 2–9 narrow Claim 1 by requiring particular meloxicam systemic exposure characteristics.
- Claims 10–12 and 17 and 29 narrow by salt forms and excipient type/amount.
- Claims 13–16 and 18–21 narrow around meloxicam and rizatriptan amounts.
- Claims 22–28 mirror the PK constrains again under the meloxicam-fixed dependent branch.
What formulation and PK elements likely control infringement: bicarbonate-driven meloxicam exposure?
Even without the specification text, the dependent claim set makes the mechanism of claim design clear: the patent is drafted to treat a bicarbonate-containing oral tablet as a way to alter meloxicam absorption rate and exposure.
Claim 1 composition implies:
- bicarbonate acts as a formulation determinant influencing meloxicam absorption kinetics.
Dependent claim PK implies:
- the tablet is expected to produce:
- meloxicam Tmax < 60 min (Claims 2 and 3),
- meloxicam Cmax around 2,500–3,000 ng/mL (Claims 4–5),
- meloxicam AUC0-inf around 50,000–70,000 ng·hr/mL (Claims 6–8),
- with half-life near 20 hours (Claim 9),
- while concomitantly producing pain reduction within about 2 hours (Claim 1).
Infringement exposure-risk:
- A competitor can avoid Claim 1 only by changing at least one required element: dose ranges, bicarbonate window/type, daily regimen, or clinical observation timing.
- A competitor can avoid dependent claims more easily by shifting PK outcomes (Tmax/Cmax/AUC) outside the specified windows, even if Claim 1 composition is similar.
Which design-arounds are most likely to be “high-friction” vs “low-friction”?
High-friction design changes (risk of hitting Claim 1)
- Using an oral migraine tablet that still contains:
- meloxicam ~20 mg,
- rizatriptan ~10 mg (or molar equivalent salt),
- bicarbonate 400–1000 mg,
- and targets pain reduction within ≤2 hours after dosing.
Lower-friction design changes (risk reduction mainly for dependent PK claims)
- Keep dose amounts similar but modify excipient system or processing to shift meloxicam PK out of:
- Tmax < 60 min (Claims 2–3),
- Cmax 2,500–3,000 ng/mL (Claims 4–5),
- AUC0-inf 50,000–70,000 ng·hr/mL (Claims 6–8),
- and/or half-life from ~20 hours (Claim 9).
- Change bicarbonate identity (to something other than sodium bicarbonate) to avoid Claim 17.
- Use a different rizatriptan salt form or different salt mass to avoid Claims 10–12 and 29 (rizatriptan benzoate).
Bottom line: the patent is not a “composition-only” claim set. It is drafted to capture both formulation and in-human performance.
Patent landscape for US 11,738,085: what is protected in the US and how is it likely positioned against generics?
The claim set reads like a defensive moat around a specific FDC product for migraine using meloxicam plus rizatriptan and bicarbonate-mediated absorption.
How many layers of protection are built into the claim set?
Based on the claim text you provided, the protection layers are:
- Method and regimen (migraine; one tablet daily).
- FDC composition (meloxicam + rizatriptan + bicarbonate at specified loads).
- Clinical endpoint timing (pain reduction at about 2 hours or less).
- Meloxicam PK characteristics (Tmax/Cmax/AUC/half-life).
- Salt identity and excipient type (sodium bicarbonate; rizatriptan benzoate).
- Salt masses (14–15 mg rizatriptan salt).
This pattern is typical of patents intended to deter both:
- “Same-dose different-formulation” entry (dependent PK claims),
- and “Different-salt” entry (dependent salt claims).
How does this affect generic or NDA-505(b)(2) entry risk?
- A generic seeking approval under an ANDA for a migraine indication would need to avoid infringement under the US patents listed for the reference product. A generic product that matches composition and dosing but differs in PK could still present infringement risk for Claim 1, depending on whether the clinical pain-time limitation is met and whether it literally/constructively meets “about” ranges.
- For Claim 2–9 and 22–28, the generic would need to show its meloxicam PK is outside each relevant window. That is often hard if the formulation is close and exposure is similar.
Litigation posture implied by claim style
Method-of-treatment and exposure-driven dependent claims usually produce two litigation focal points:
- whether the accused product’s administered tablet matches the composition windows (doses and bicarbonate amount),
- whether the accused product meets the PK and clinical endpoints.
What does the claim language imply about the commercial product format?
Likely product profile
- oral solid dosage form (tablet) with a bicarbonate content that is large enough to materially impact tablet behavior and absorption kinetics.
- fixed daily dosing (one tablet per day), suggesting the tablet is intended to be taken during migraine episodes or a defined regimen that still uses one daily tablet.
- meloxicam is positioned as a “rapid-onset exposure contributor” via PK manipulation (Tmax, Cmax, AUC), while rizatriptan contributes migraine relief.
How do claims read across meloxicam dose and rizatriptan salt form?
The claims separate:
- meloxicam content: broadly “about 20 mg” in Claim 1 and specifically “about 20 mg” in Claim 13 and Claim 18.
- rizatriptan content:
- Claim 1: about 10 mg rizatriptan (molar equivalent salt).
- Dependent set: 14 mg / 15 mg / 14–15 mg of a salt form (Claims 10–12, and corresponding branches).
- salt identity in Claim 29: rizatriptan benzoate.
- bicarbonate:
- Claim 1: about 400–1000 mg bicarbonate.
- Claim 17: sodium bicarbonate.
Legal reading: the patent likely covers a formulation where the rizatriptan free base amount corresponds to a different salt mass in the tablet. The dependent claims capture salt-specific weights and identity.
Key Takeaways
- US 11,738,085 is drafted as an FDC method-of-treating migraine claim anchored in a specific oral tablet composition: meloxicam (~20 mg) + rizatriptan (~10 mg) + bicarbonate (400–1000 mg), dosed once daily, with pain reduction observed at about ≤2 hours.
- The infringement risk intensifies under dependent claims because they require meloxicam PK outcomes: Tmax < 60 minutes (or ~50 minutes), Cmax around 2,500–3,000 ng/mL, AUC0-inf around 50,000–70,000 ng·hr/mL, and half-life near 20 hours.
- Salt and excipient identity matter: sodium bicarbonate (Claim 17) and rizatriptan benzoate (Claim 29) are explicitly claimed via dependencies.
- Design-arounds that change only one component (for example, rizatriptan salt identity or bicarbonate type) may avoid some dependent claims but still leave exposure on Claim 1 if composition and clinical timing still match.
- For generics and 505(b)(2) competitors, the central technical hurdle is demonstrating meloxicam PK is outside the specific windows and that the product does not meet the clinical “pain reduction at about two hours or less” limitation.
FAQs
- Can a competitor avoid infringement of Claim 1 by changing bicarbonate amount slightly outside 400–1000 mg?
- Do the dependent PK claims (Tmax/Cmax/AUC) create separate infringement hooks even if composition matches Claim 1?
- How does specifying “about 2 hours or less” constrain method-of-use infringement for migraine patients?
- If a product uses a rizatriptan salt other than benzoate, does it still risk Claims 10–12 equivalents?
- What evidence is most likely used in litigation to prove meloxicam Tmax/Cmax/AUC after dosing of the accused tablet?
References
- United States Patent 11,738,085, claims 1–29 (provided).
More… ↓
⤷ Start Trial
|
